Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.

@article{Hopkins2013EffectsO6,
  title={Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.},
  author={Nicola Dominique Hopkins and Daniel J Cuthbertson and Graham J. Kemp and Christopher J A Pugh and Daniel John Green and Nigel Timothy Cable and Helen Jones},
  journal={Diabetes, obesity & metabolism},
  year={2013},
  volume={15 8},
  pages={770-3}
}
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are used for treatment in type 2 diabetes mellitus (T2DM). Little is known about their cardiovascular (CV) impact. We sought to determine the effects of chronic treatment on vascular function in T2DM. Brachial artery endothelial-dependent flow-mediated dilation (FMD) and endothelial-independent glyceryl trinitrate (GTN) function and carotid intima-medial thickness (cIMT) were assessed in 11 severely obese T2DMs (4 females, 7 males: 55 ± 8… CONTINUE READING